Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litifilimab in Cutaneous Lupus Erythematosus (AMETHYST)
NCT05531565Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Sep 2022
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of litifilimab in cutaneous lupus erythematosus (CLE), sponsored by Biogen. Started Sep 2022; status: active, not recruiting.
02
Drugs
litifilimab
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05531565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531565.